Table 4.

Results of Various Studies^3,21 Related to the Future Treatments of SSPE Including Fusion Inhibitor Peptides, RNA Polymerase Inhibitors and Neutralizing Antibody-Derived Molecules.

Study name	Author (s)	Location	Study type	Result (s)
Subacute sclerosing panencephalitis 3	Ravindra Kumar Garg, Anita Mahadevan, Hardeep Singh Malhotra Imran Rizvi, Neeraj Kumar, Ravi Uniyal	India	Review	Fusion inhibitor peptides (compound AS-48) that bind to the viral fusion proteins are being developed as potential therapeutic agents
Advances in antiviral therapy for subacute sclerosing panencephalitis 21	Koichi Hashimoto, Mitsuaki Hosoya	Japan	Review	An RNA-Polymerase inhibitor, Favipiravir could also be exploited for the treatment of SSPE in the future
Advances in antiviral therapy for subacute sclerosing panencephalitis 21	Koichi Hashimoto, Mitsuaki Hosoya	Japan	Review	Neutralizing antibody-derived molecules such as single-strand variable fragments that target the H protein are possible candidates for the treatment of SSPE